Elimination of Egfr-Overexpressing Cancer Cells by CD32 Chimeric Receptor T Cells in Combination with Cetuximab or Panitumumab

Sara Caratelli(National Academies of Sciences, Engineering, and Medicine), Giuseppe Sconocchia(National Academies of Sciences, Engineering, and Medicine)
bioRxiv (Cold Spring Harbor Laboratory)
March 18, 2019
10.1101/581017
Cited by 0

Related Papers

<i>In vitro</i> elimination of epidermal growth factor receptor‐overexpressing cancer cells by CD32A‐chimeric receptor T cells in combination with cetuximab or panitumumab
|International Journal of Cancer|2019|40
CD16-158-Valine Chimeric Receptor T Cells Overcome the Resistance of KRAS-mutated Colorectal Carcinoma Cells to Cetuximab
|bioRxiv (Cold Spring Harbor Laboratory)|2019|3
The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity
|Experimental Hematology and Oncology|2025|2
Antibody-Independent Antitumor Effects of Cd32A-Chimeric Receptor T Cells: Implications for Breast Cancer Prognosis and Treatment
|bioRxiv (Cold Spring Harbor Laboratory)|2021|1
The CD64/CD28/CD3 ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity
|Research Square|2024|0